# Safety and Efficacy of Docetaxel, Darolutamide, and Homoharringtonine Combined With Androgen Deprivation Therapy in Neoadjuvant Treatment of High-Risk Prostate Cancer: A Multicenter Prospective, Single-Arm Clinical Study

> **NCT07516704** · EARLY_PHASE1 · NOT_YET_RECRUITING · sponsor: **Zhongda Hospital** · enrollment: 94 (estimated)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** Docetaxel+ Darolutamide + Homoharringtonine+ Androgen Deprivation Therapy

## Key facts

- **NCT ID:** NCT07516704
- **Lead sponsor:** Zhongda Hospital
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-04-01
- **Primary completion:** 2027-12-01
- **Final completion:** 2027-12-12
- **Target enrollment:** 94 (ESTIMATED)
- **Last updated:** 2026-04-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07516704

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07516704, "Safety and Efficacy of Docetaxel, Darolutamide, and Homoharringtonine Combined With Androgen Deprivation Therapy in Neoadjuvant Treatment of High-Risk Prostate Cancer: A Multicenter Prospective, Single-Arm Clinical Study". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07516704. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*